<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192565</url>
  </required_header>
  <id_info>
    <org_study_id>CMX-CSP-CS002</org_study_id>
    <nct_id>NCT04192565</nct_id>
  </id_info>
  <brief_title>A Prospective Investigation of the ColubrisMX ELS System</brief_title>
  <official_title>A Prospective Investigation of the ColubrisMX Endoluminal Surgical (ELS) System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ColubrisMX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ColubrisMX</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single-arm, open-label, multi-center, feasibility study to&#xD;
      evaluate the safety and efficacy of ColubrisMX ELS System in patients undergoing transanal&#xD;
      endoluminal procedures, specifically colorectal Endoscopic Submucosal Dissection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current treatment options for colorectal lesions most often include flexible endoscopy or&#xD;
      open/laparoscopic surgery. Both approaches have procedural limitations that can have&#xD;
      considerable impact on patient care. Traditional endoscopic tools have technical&#xD;
      inadequacies, ones that inhibit the physician's ability to complete more complex tasks&#xD;
      consistent with a surgical technique. Conversely a traditional open or laparoscopic surgical&#xD;
      approach involves increased chance of complications (such as surgical site infection), more&#xD;
      pain &amp; blood loss, longer recovery and larger surgical scars.&#xD;
&#xD;
      This clinical study proposes the use of an endoluminal robotic technology that is designed to&#xD;
      improve patient outcomes for colorectal lesions. This system allows physicians to perform&#xD;
      many types of complex endoluminal procedures with more precision, flexibility, and control&#xD;
      than that of conventional endoscopic, open or laparoscopic surgical techniques. Using this&#xD;
      robotic system, surgeons can perform delicate and complex endoluminal procedures that may&#xD;
      have been difficult or impossible with other methods, and could have positive impact on&#xD;
      outcomes, recovery time, and overall patient care.&#xD;
&#xD;
      Patients will undergo the procedure using the ColubrisMX ELS System, and its initial safety&#xD;
      and efficacy outcomes will be assessed intraoperatively and postoperatively at discharge and&#xD;
      days 7 and 30.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Actual">March 29, 2021</completion_date>
  <primary_completion_date type="Actual">March 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of success</measure>
    <time_frame>24 hours post-op</time_frame>
    <description>Percentage of patients with no conversion during surgery and no major complications (Clavien-Dindo ≥ 3 complication rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Conversion</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Percentage of patients with a change in treatment plan to a conventional open or laparoscopic procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate (%)</measure>
    <time_frame>Intraoperatively and postoperatively at Days 7 and 30.</time_frame>
    <description>Percentage of patients having Clavien-Dindo ≥ 3</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Polyp</condition>
  <condition>Colorectal Adenoma</condition>
  <condition>Colorectal Adenomatous Polyp</condition>
  <arm_group>
    <arm_group_label>Robotic Endoluminal Resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Robotic resection of mucosal lesions of the colon and rectum</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Robotic Endoluminal Resection</intervention_name>
    <description>Robotic Resection of mucosal neoplasms in the colon and rectum using the ColubrisMX ELS system</description>
    <arm_group_label>Robotic Endoluminal Resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        13 INCLUSION CRITERIA&#xD;
&#xD;
        All of the following criteria must be present to be eligible for the study:&#xD;
&#xD;
          1. Aged 18-75 years&#xD;
&#xD;
          2. BMI ≤ 35 kg/m2&#xD;
&#xD;
          3. Patient agrees to participate in the study by giving signed informed consent&#xD;
&#xD;
          4. Benign lesions of the rectum, such as adenoma, submucosal nodule, or polyp&#xD;
&#xD;
          5. Mucosal neoplasm&#xD;
&#xD;
          6. Eligible to undergo standard endoscopic submucosal dissection.&#xD;
&#xD;
          7. Patient reviewed and approved by Local Oncology Committee to undergo robotic&#xD;
             procedure.&#xD;
&#xD;
        14 EXCLUSION CRITERIA&#xD;
&#xD;
        Patients will be excluded from the study if any of the following criteria are present:&#xD;
&#xD;
        Preoperative&#xD;
&#xD;
          1. Anatomy unsuitable for endoscopic visualization or endoluminal surgery&#xD;
&#xD;
          2. Extensive previous surgery in the lower GI tract&#xD;
&#xD;
          3. Prior radiation treatment for colorectal cancer&#xD;
&#xD;
          4. Patient with distant metastases&#xD;
&#xD;
          5. Untreated active infection&#xD;
&#xD;
          6. Vulnerable population (e.g., prisoners, mentally disabled)&#xD;
&#xD;
          7. Severe concomitant illness (i.e., cancer) that drastically shortens life expectancy or&#xD;
             increases risk of therapeutic interventions&#xD;
&#xD;
          8. Breastfeeding or pregnant, or intend to become pregnant during the course of the study&#xD;
&#xD;
          9. Currently enrolled in or discontinued within the last 30 days from a clinical trial of&#xD;
             an investigational drug or device, or concurrently enrolled in any other type of&#xD;
             medical research judged not to be scientifically or medically compatible with this&#xD;
             study&#xD;
&#xD;
         10. In the opinion of the Investigator, the patient is unable to comply with the&#xD;
             requirements of the study protocol or is unsuitable for the study for any reason.&#xD;
&#xD;
         11. Patients with immunosuppression drugs (chemotherapy) due to an increase potential&#xD;
             infection and poor healing&#xD;
&#xD;
         12. Patients with a high cardiac or pulmonary risk (these patients require clearance from&#xD;
             a cardiologist and pulmonologist)&#xD;
&#xD;
         13. Preoperative blood thinner i.e., coumadin or heparin.&#xD;
&#xD;
         14. Obstructing rectal cancer&#xD;
&#xD;
         15. History of inflammatory bowel disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Grecco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Colorectal Polyp</keyword>
  <keyword>Colorectal Adenoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

